Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression

Abstract Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined. However, it is necessary to take into account all the properties of propranolol to select a d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laura Brohée, Olivier Peulen, Betty Nusgens, Vincent Castronovo, Marc Thiry, Alain C. Colige, Christophe F. Deroanne
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/76f47ad4a6c14361aa10363a8d4226c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76f47ad4a6c14361aa10363a8d4226c1
record_format	dspace
spelling	oai:doaj.org-article:76f47ad4a6c14361aa10363a8d4226c12021-12-02T12:32:10ZPropranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression10.1038/s41598-018-25340-92045-2322https://doaj.org/article/76f47ad4a6c14361aa10363a8d4226c12018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-25340-9https://doaj.org/toc/2045-2322Abstract Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined. However, it is necessary to take into account all the properties of propranolol to select a drug that could be efficiently combined with. Propranolol was reported to block the late phase of autophagy. Hence, we hypothesized that in condition enhancing autophagy flux, cancer cells should be especially sensitive to propranolol. 2DG, a glycolysis inhibitor, is an anti-tumor agent having limited effect in monotherapy notably due to induction of pro-survival autophagy. Here, we report that treatment of cancer cells with propranolol in combination with the glycolysis inhibitor 2DG induced a massive accumulation of autophagosome due to autophagy blockade. The propranolol +2DG treatment efficiently prevents prostate cancer cell proliferation, induces cell apoptosis, alters mitochondrial morphology, inhibits mitochondrial bioenergetics and aggravates ER stress in vitro and also suppresses tumor growth in vivo. Our study underlines for the first time the interest to take advantage of the ability of propranolol to inhibit autophagy to design new anti-cancer therapies.Laura BrohéeOlivier PeulenBetty NusgensVincent CastronovoMarc ThiryAlain C. ColigeChristophe F. DeroanneNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-14 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Laura Brohée Olivier Peulen Betty Nusgens Vincent Castronovo Marc Thiry Alain C. Colige Christophe F. Deroanne Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
description	Abstract Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined. However, it is necessary to take into account all the properties of propranolol to select a drug that could be efficiently combined with. Propranolol was reported to block the late phase of autophagy. Hence, we hypothesized that in condition enhancing autophagy flux, cancer cells should be especially sensitive to propranolol. 2DG, a glycolysis inhibitor, is an anti-tumor agent having limited effect in monotherapy notably due to induction of pro-survival autophagy. Here, we report that treatment of cancer cells with propranolol in combination with the glycolysis inhibitor 2DG induced a massive accumulation of autophagosome due to autophagy blockade. The propranolol +2DG treatment efficiently prevents prostate cancer cell proliferation, induces cell apoptosis, alters mitochondrial morphology, inhibits mitochondrial bioenergetics and aggravates ER stress in vitro and also suppresses tumor growth in vivo. Our study underlines for the first time the interest to take advantage of the ability of propranolol to inhibit autophagy to design new anti-cancer therapies.
format	article
author	Laura Brohée Olivier Peulen Betty Nusgens Vincent Castronovo Marc Thiry Alain C. Colige Christophe F. Deroanne
author_facet	Laura Brohée Olivier Peulen Betty Nusgens Vincent Castronovo Marc Thiry Alain C. Colige Christophe F. Deroanne
author_sort	Laura Brohée
title	Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
title_short	Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
title_full	Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
title_fullStr	Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
title_full_unstemmed	Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
title_sort	propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/76f47ad4a6c14361aa10363a8d4226c1
work_keys_str_mv	AT laurabrohee propranololsensitizesprostatecancercellstoglucosemetabolisminhibitionandpreventscancerprogression AT olivierpeulen propranololsensitizesprostatecancercellstoglucosemetabolisminhibitionandpreventscancerprogression AT bettynusgens propranololsensitizesprostatecancercellstoglucosemetabolisminhibitionandpreventscancerprogression AT vincentcastronovo propranololsensitizesprostatecancercellstoglucosemetabolisminhibitionandpreventscancerprogression AT marcthiry propranololsensitizesprostatecancercellstoglucosemetabolisminhibitionandpreventscancerprogression AT alainccolige propranololsensitizesprostatecancercellstoglucosemetabolisminhibitionandpreventscancerprogression AT christophefderoanne propranololsensitizesprostatecancercellstoglucosemetabolisminhibitionandpreventscancerprogression
_version_	1718394166280454144

Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression

Ejemplares similares